Last reviewed · How we verify
idelalisib and rituximab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
idelalisib and rituximab (idelalisib and rituximab) — Gruppo Italiano Malattie EMatologiche dell'Adulto.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| idelalisib and rituximab TARGET | idelalisib and rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- idelalisib and rituximab CI watch — RSS
- idelalisib and rituximab CI watch — Atom
- idelalisib and rituximab CI watch — JSON
- idelalisib and rituximab alone — RSS
Cite this brief
Drug Landscape (2026). idelalisib and rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/idelalisib-and-rituximab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab